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Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer and 
annually an approximate 46,000 Americans are diagnosed and 8,600 Americans die from the 
disease. The oncogenic transcription factor STAT3 is frequently hyper-activated in HNSCC and 
promotes gene transcription involved in cancer development, maintenance and progression. 
Several selective small molecule inhibitors of IL-6-induced STAT3 activation were identified in 
a screening campaign, and four analogs from a lead optimization series were analyzed to 
promote one to test in vivo. 
To choose a lead compound for in vivo experimentation, the four compounds were 
incubated with mouse liver microsomes to select a lead based on enhanced metabolic stability.  
From this experiment compound UPCDC-10205 was prioritized for in vivo testing to evaluate its 
toxicity, pharmacokinetics (PK) and metabolism. Both single and multiple IV dose toxicity 
studies determined that the maximum soluble dose at 4 mg/kg of compound UPCDC-10205 in 
10% Solutol™ was not toxic to mice. To evaluate PK, single doses of UPCDC-10205 IV 4 
mg/kg, PO 4 mg/kg, or PO 30 mg/kg UPCDC-10205 suspension in 1% carboxymethyl cellulose 
were administered to groups of female mice that were euthanized from 5 min to 24 h after 
dosing.  Plasma, urine and various tissues were analyzed using LC-MS to quantitate UPCDC-
10205. PK parameters were determined non-compartmentally. Potential metabolites were 
monitored in plasma and urine using LC-MS. 
PK analysis showed rapid plasma clearance and extensive distribution of UPCDC-10205. 
Comparisons of plasma exposure between 4 mg/kg PO and IV showed a bioavailability of ~5%. 
Little UPCDC-10205 was observed in urine, leading to the hypothesis that metabolism was the 
major contributor to clearance. Metabolic investigations revealed direct glucuronidation as the 
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major metabolite, explaining why microsomal stability (reflective of phase I metabolism) did not 
translate to in vivo metabolic stability. 
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1.0  INTRODUCTION 
1.1 HEAD AND NECK SQUAMOUS CELL CARCINOMA  
Head and neck squamous cell carcinoma (HNSCC) accounts for 90% of diagnosed head 
and neck cancers and originates from the epithelium of the pharynx and oral cavities.
1
 The 
development of HNSCC has been correlated with a variety of factors, including tobacco use and 
human papilloma virus.
2, 3
 HNSCC is the sixth most common cancer with approximately 46,000 
Americans diagnosed and 8,600 Americans dying from the disease annually.
1, 4
 Men account for 
approximately 70% of those afflicted and dying.
4
 Five year survival rates for all stages of head 
and neck cancer are 60% with only modest improvements within the past 40 years.
1
 The majority 
of diagnoses are of advanced stage and 60% of patients will also have recurrent or metastatic 
disease.
1, 5
 Patients diagnosed with recurrent or metastatic HNSCC currently have no curative 
options.
5
 The current standard of care for HNSCC varies depending on disease site and stage, but 
treatment usually involves combinatorial surgery and radiation.
1
 Chemotherapeutic options for 
late stage HNSCC are considered palliative and no current therapies have demonstrated a proven 
benefit to survival.
1
 Due to these factors, there has been an urgent and unmet need to identify 
new chemotherapeutic options for HNSCC and increase survival rates, especially in cases of 
recurrent and metastatic HNSCC. 
 15 
1.2 STAT3  
Signal transducer and activator of transcription 3 (STAT3) activation has been implicated 
in most cancer types including HNSCC.
1, 6-10
 STAT3 has been found to be constitutively active 
in HNSCC cell lines and tumors.
6, 10
 Identification of this biomarker and elucidation of its 
contributions to carcinogenesis may help to identify new therapies to combat the disease.
1, 9
 
STAT3 has also been used as a prognostic factor for staging the disease, with increased STAT3 
activation translating to a poorer clinical outcome.
8
 Aberrant STAT3 activation can lead to the 
initiation, development and metastasis of cancers by misregulating the genes and proteins needed 
to overcome cancer progression barriers.
6, 7, 9, 11, 12
 As well as directly manipulating gene 
expression, STAT3 has been found to alter expression non-directly by epigenetic DNA 
methylation.
13
 STAT3 has also been shown to play a role in chemoradiotherapy resistance.
14
 
Understanding the STAT3 pathway and its involvement in cancer pathophysiology may help 
researchers and clinicians modulate its effects in cancer and other diseases. 
1.2.1 STAT3 Pathway 
STAT3 is part of a seven member protein family that act as cytosolic signal transducers 
and transcription factors that regulate gene transcription.
6, 8, 9, 15
 STAT members are structurally 
similar and have overlap in gene transcription, although each has unique targets of 
transcription.
6, 8
 STAT transcriptional activation requires phosphorylation on a single tyrosine 
residue towards its carboxyl terminus (Tyr705).
6-9, 15
 This phosphorylation is usually initiated in 
response to upstream cytokines or growth factors that activate their respective receptor or 
associated kinases which are then able to directly phosphorylate specific STAT family 
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members.
6, 8, 15
 Upon phosphorylation by an upstream kinase, STAT proteins dimerize and 
translocate to the nucleus where they can act as transcription factors by binding to promoter 
regions of their regulated genes.
6, 8, 16
 Figure 1 shows a simplified STAT3 activation pathway. 
 
Figure 1. Schematic representation of STAT signaling pathways.
17
 
1.2.2 STAT3’s Role in Cancer 
Within the STAT family, STAT3 has been found to regulate functions such as cellular 
proliferation, cell cycle progression, apoptosis, angiogenesis, immune invasion, survival, 
inflammation, invasion and metastasis.
6-8, 11, 16, 18
 In non-disease states, interleukin-6 (IL-6) 
induced STAT3 activation is used to provide survival cues and block apoptosis during 
inflammatory processes.
19
 Cancer development can hijack the IL-6/STAT3 signaling pathway to 
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constitutively activate STAT3 and promote carcinogenesis. In cancer cells, STAT3 has also been 
shown to silence its negative regulator, SOCS (suppressor of cytokine signaling).
8
 The link 
between constitutively activated STAT3 signaling and cancer earned STAT3 the label of 
oncogene.
6, 7
 STAT3’s role as a point of convergence for multiple cancerous pathways has made 
it an attractive target for the development of new chemotherapeutic therapies. 
EGF/EGFR and IL-6/IL-6R have been identified as primary, but not the only, regulators 
of STAT3 phosphorylation and treatments that target these pathways are currently being 
pursued.
6, 7, 13
 EGFR modulating chemotherapies have become promising agents for HNSCC but 
so far drugs targeting EGFR signaling have been found to only offer disease control and offer 
palliative care, with no tumor regression in HNSCC.
1, 7
 Additionally, evidence has shown that 
eventual drug resistance is developed against EGFR inhibitors.
5, 7
 One reason for resistance is 
that there are multiple pathways that lead to STAT3 activation besides EGFR, suggesting that 
other STAT3 activators, such as IL-6, should be targeted for STAT3 modulation.
5
 A growing 
body of evidence has implicated IL-6 production in HNSCC cells as the predominant activator of 
STAT3.
10
 Investigations of STAT3 activation in HNSCC cell lines have shown that even in 
EGFR-positive lines, STAT3 activation is not dependent on EGFR activation.
10
 Subsequently, 
depletion of IL-6, blocking the IL-6R subunit (gp130) or the IL-6R associated intracellular 
kinase (Janus kinase of JAK), leads to decreased activated STAT3 (pSTAT3).
6, 10
 This research 
implicates IL-6 is the primary factor for STAT3 activation in HNSCC.
10
 Clinically, both 
increased IL-6 and pSTAT3 levels have been associated with a poorer prognosis for those with 
cancer.
8, 13
 Serum IL-6 levels have also been used to predict HNSCC patient survival.
20-22
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1.2.3 STAT3 as a Target 
Targeting IL-6 induced STAT3 activation in HNSCC has been a logical target to develop 
therapies. IL-6 has been described as the traditional activator of STAT3.
13
 Canonical IL-6 
signaling pathway requires IL-6 to bind to its receptor, IL-6Rα.13, 23 This interaction causes the 
recruitment of gp130 subunits to the ligand-receptor complex.
13, 23
 Two of these complexes 
interact together to form a hexamer that in turn causes intracellular autophosphorylation of 
JAKs.
13, 23
 Activated JAKs are able to phosphorylate STAT3 proteins on their tyr-705 residue.
23
 
Two phosphorylated STAT3 proteins then homodimerize, which allows for the translocation of 
the dimer into the nucleus where it can act as a transcription factor.
13, 23
 
Despite the growing amount of literature that implicates STAT3 in cancer development 
and progression, there are currently no approved therapies that directly target STAT3.
13
 Several 
strategies to inhibit IL-6 induced pSTAT3 in HNSCC have been evaluated, with each targeting 
specific parts of the signaling cascade. STAT3 decoy oligonucleotides have been developed that 
act by binding pSTAT3 in the cytosol and inhibit its function as a transcription factor.
24
 Another 
strategy is the use of IL-6R monoclonal antibodies, which are currently being used clinically to 
treat rheumatoid arthritis.
25
 Many small molecule inhibitors of pSTAT3 have been identified and 
are in various phases of preclinical and clinical development.
9, 26
 Some, such as OPB-31121, 
have clinically demonstrated antitumor activity.
27
 
One consideration when targeting IL-6 induced pSTAT3 inhibition is specificity. Due to 
the structural homology of STAT family members (Figure 2), a drug targeting STAT3 should be 
selective and not interfere with functions of other STAT members, particularly STAT1 which 
acts a tumor suppressor.
8, 28
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Figure 2. Structures of STAT family members.
17
 
 
STAT1 is the singular downstream target of interferon-γ (IFN-γ) signaling.8 Many of the 
genes it promotes are antagonistic to those of STAT3.
28, 29
 STAT1 provides anti-proliferative, 
pro-apoptotic, and immune system recruitment and in its own right could serve as a therapeutic 
target.
28, 30
 
STAT1 phosphorylation, similar to STAT3, is accomplished through intracellular JAKs 
that are activated by IFN-γ binding to its cognate receptor.31 Due to the overlap in utilization of 
JAKs and the structural homology between STAT1 and STAT3, an ideal small molecule 
inhibitor of pSTAT3 should demonstrate specificity to preserve the tumor suppressive function 
of STAT1.
15, 16, 30
 Targeting IL-6 induced STAT3 activation may lead to less off-target effects, 
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especially in HNSCC, where elevated levels of IL-6 are present in the local tumor environment, 
and prevent suppression of STAT1 signaling.
20
 
1.3 CAMPAIGN TO IDENTIFY AN IL-6 INDUCED STAT3 INHIBITOR 
Recently, a high content screen was developed and validated using HNSCC cell lines to 
identify novel small molecule inhibitors of IL-6 induced pSTAT3.
32
 This screen identified 1,068 
active hits from a 94,491 compound library. Active hits from the screen were confirmed with 
pSTAT3 IC50 assays and prioritized using an assay quantifying IFN-γ induced pSTAT1 
activation.
33
 Forty-nine compounds met the following selection criteria: reproducibly inhibiting 
IL-6-induced pSTAT3 activation by at least 70% at 20 µM; pSTAT3 activation IC50s less than 
25 µM; and at least 2-fold selective for pSTAT3 inhibition over pSTAT1 inhibition.
33
 From the 
forty-nine compounds, a group of four triazolothiadiazine analogues (Figure 3), named the 669 
series, were chosen for in vivo consideration based on chemical tractability and favorable in 
silico ADME-Tox attributes.
33
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Figure 3. Structures for the selected four IL-6 induced STAT3 inhibitor analogues from the 669 series. 
 
To identify a lead candidate for in vivo examination among the four analogues in the 669 
series, a mouse liver microsome incubation was conducted to identify the most metabolically 
stable compound of the series. It is common practice to prioritize a lead candidate using in vitro 
techniques, such as cyp P450 screens, to prioritize for metabolic stability because metabolism 
can directly affect toxicity, bioavailability, and clearance.
34, 35
 To prioritize an analogue by 
metabolic stability, a microsome incubation experiment was used to assess which analogue had 
the most parent compound remaining after a 90 min incubation. Compound concentrations were 
monitored for this determination using LC-MS. The prioritized compound was then examined in 
vivo by conducting toxicity and pharmacokinetic (PK) studies. Toxicity was assessed in separate 
 22 
single and multiple dose studies to determine acute toxicity as well as establishment of a 
maximum tolerable dose (MTD). The PK study examined intravenous (IV) and oral (PO) 
administration of the compound in solution (10% Solutol™ HS15) as well as PO administration 
with a 1% carboxymethyl cellulose (CMC) suspension. Compound concentrations were 
measured in plasma and tissues using a sensitive LC-MS/MS assay to determine PK parameters 
and bioavailability. Using LC-MS, the metabolic fate of the compound was determined in vivo 
and the biotransformation confirmed by replicating it in vitro. 
  
 23 
2.0  MATERIALS AND METHODS 
2.1 CHEMICALS AND SOLVENTS 
Compounds UPCDC-10205, UPCDC-10305, 864669, and UPCDC-10540 were 
synthesized and provided by the University of Pittsburgh Chemical Diversity Center (Pittsburgh, 
PA). The internal standard 
2
H7-UPCDC-10205 ([
2
H7]-3-(3-(4-chlorophenyl)-1H-pyrazole-5-yl)-
6-(4-methoxyphenyl)-7-methyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine) was custom 
synthesized and purchased from ALSACHIM (Illkirch-Graffenstaden, France). Water and 
acetonitrile (both HPLC grade), formic acid, monobasic and dibasic KPO4, tris and DMSO were 
obtained through Fisher Scientific (Fairlawn, NJ). Bovine serum albumin (BSA), NADPH, 
carboxymethyl cellulose (suspending agent), UDPGA, MgCl2, alamethicin, formic acid and 
Solutol™ HS 15 were purchased from Sigma-Aldrich (St. Louis, MO).  
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2.2 SELECTION OF IN VIVO CANDIDATE 
2.2.1 Preparation of Mouse Tissue Homogenates and Hepatic Fractions and Incubation 
with STAT3 Inhibitors 
Microsomes were prepared and isolated from livers of heterozygous athymic Nude-
Foxn1
nu
/Foxn1
+
 female mice as previously published.
36
 The microsomal pellet was stored at -80 
°C until measurement of protein concentration using a protein assay kit from BioRad (Hercules, 
CA) with BSA as the standard. Absorbance readings were recorded at 630 nm using an Infinite 
M100 Pro plate reader from Tecan (Männedorf, Switzerland). Actual incubation volumes were 
adapted from the published method to allow for a 200 µL incubation volume. 
The 200 µL incubation contained 0.5 mg/mL microsomal protein, 1,000 ng/mL drug 
concentration, 1 µM NADPH, 0.1 M phosphate buffer (pH 7.4) and less than 0.1% acetontrile. 
The incubation was terminated with 1.0 mL acetonitrile. Sample times (point of organic reaction 
termination) were performed in triplicate at 0 (acetonitrile added prior to addition of 
microsomes), 15, 30, 45, 60 and 90 min. LMP400 (0 and 90 min incubations) was used as a 
positive control. Respective internal standard (10 µL of 1.0 µg/mL) of either UPCDC-10540 or 
UPCDC-10205 was added to samples, followed by briefly vortexing and storage at -80 °C until 
LC-MS analysis. 
2.2.2 Microsome Incubation LC-MS 
An LC-MS method was developed to simultaneously quantitate the four STAT3 inhibitor 
analogues. Two separate MS methods (using identical LC-MS conditions) were utilized. 
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Compound UPCDC-10540 was used as an internal standard to quantitate compounds 864669, 
UPCDC-10305 and UPCDC-10205. Compound UPCDC-10205 was used as an internal standard 
to quantitate compound UPCDC-10540. 
The HPLC method consisted of an Agilent 1100 autosampler and Agilent 1100 binary 
pump (Agilent Technologies, Palo Alto, CA) using a Synergi Hydro-RP 80A (4 µm particle size, 
2 mm x 100 mm) column at ambient temperature. Mobile phase solvent A was 0.1% formic acid 
(v/v) in acetonitrile, and mobile phase solvent B was 0.1% formic acid (v/v) in water. The initial 
mobile phase was composed of 55% solvent A pumped at 0.3 mL/min for 5.0 min, changed to 
99% solvent A and was held there for 1.0 min. At 6.1 min the percentage of solvent A returned 
to initial conditions of 55% for 4 min followed by injection of the next sample. Total run time 
was 10 min. Retention times were as follows: 3.4 min for 864669, 4.6 min for UPCDC-10205, 
4.2 min for UPCDC-10305, and 4.9 min for 540 and a representative chromatogram in Figure 4. 
A Quattro Micro mass spectrometer (Waters Corporation, Milford, MA) was used in positive-ion 
SRM mode (4.0 kV capillary voltage, 40V cone voltage) to monitor m/z 391.0 for 864669, m/z 
409.0 for UPCDC-10305, m/z 437.0 for UPCDC-10205, and m/z 416.0 for UPCDC-10540. 
 26 
 
Figure 4. Representative chromatogram of a 500 ng/mL calibrator from the LC-MS assay to quantitate the 
selected 669 series analogues for the microsome incubation. Peak A is 864669, B is UPCDC-10305, C is UPCDC-
10205, and D is UPCDC-10540. 
2.2.3 Microsome Incubation LC-MS/MS Sample Preparation 
Calibrators (30, 100, 300, 500, and 1000 ng/mL) were made in a 0.1M phosphate buffer 
(pH 7.4) that contained 0.5 mg/mL BSA to match the protein concentration of the microsomes 
incubation samples. A volume of 0.2 mL of the buffer mixture was placed into a 1.5 mL 
microcentrifuge tube. An internal standard solution (10 µL of 10 µg/mL) was added to each tube 
before being briefly vortexed. A volume of 1.0 mL of acetonitrile was then added and the 
samples vortexed for 1 minute. Samples were then centrifuged at 14,000 x g for 4 min. The dried 
supernatant was resuspended in 100 µL of starting condition mobile phase. The sample injection 
volume was 5 µL. A triplicate standard curve was prepared and analyzed for accuracy (expressed 
as bias) and precision prior to sample analysis. 
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2.3 TOXICITY STUDIES 
2.3.1 Mice 
Mice were specific pathogen-free, heterozygous Foxn1
nu
/Foxn1
+
 mice (50, 5-7 weeks of 
age) purchased from Envigo (Indianapolis, IN, USA). Mice were allowed to acclimate to the 
University of Pittsburgh Animal Facility for at least 1 week before studies were initiated. To 
minimize exogenous infection, mice were maintained in microisolator cages and handled in 
accordance with the Guide for the Care and Use of Laboratory Animals (National Research 
Council, 2011) and on a protocol approved by the University of Pittsburgh IACUC. Ventilation 
and airflow in the animal facility was set to 12 changes/h. Room temperature was regulated at 72 
± 4 °F and the rooms were kept on automatic 12-h light/dark cycles. The mice received Prolab 
ISOPRO RMH 3000, Irradiated Lab Diet (PMI Nutrition International, Brentwood, MO) and 
water ad libitium. Mice were fasted overnight prior to administration of UPCDC-10205. Mice 
were stratified based on body weights into time point groups to eliminate statistical differences in 
body weight. Mice were euthanized by CO2. 
2.3.2 Dosing 
The vehicle 10% Solutol™ HS15 in sterile water provided the maximum solubilized 
concentration of UPCDC-10205 at 0.4 mg/mL and was administered to mice at a volume of 0.01 
ml/g body weight as was the vehicle (10% Solutol™ in sterile water). Mice were dosed IV at 4 
mg/kg using this solution for toxicity studies. This formulation was also delivered IV or PO for 
the PK study. A second UPCDC-10205 PO formulation was used for the PK study using 30 
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mg/kg carboxymethyl cellulose (CMC) suspension. Other formulations could not increase the 
maximum soluble dose. Dosing was accomplished for IV using ½ cc syringes with 27 gauge low 
dead volume needles and PO using 20 gauge 1½ inch feeding needles and 1 cc syringes. 
2.3.3 Single Dose Toxicity Study 
A single dose of UPCDC-10205 (at a total dose of 4 mg/kg, 0.01 ml/g body weight) was 
administered to both male and female mice (5 per group) IV by lateral tail vein injection along 
with mice administered a vehicle control. The 4 mg/kg UPCDC-10205 was formulated in water 
with 10% Solutol™ HS. After the single dose, mice were observed for a 14 day period to 
monitor clinical health, and body weights were recorded twice weekly. After the observation 
period, necropsies were performed on the mice to identify gross pathologies. 
2.3.4 Multiple Dose Toxicity Study 
For the multiple dose toxicity study, 5 female mice per treatment group were 
administered UPCDC-10205 daily (diluted to a total injection volume of 0.01 ml/g body weight) 
for 5 days IV by lateral tail vein in addition to mice administered a vehicle control. UPCDC-
10205 doses used were the single dose MTD (4 mg/kg), 2/3 the single dose MTD (2.7 mg/kg) 
and 1/3 the single dose MTD (1.3 mg/kg). All doses were formulated to have 10% Solutol™. 
After the 5 day treatment, mice were observed for a 14 day period where clinical health was 
checked daily and body weights were measured twice weekly. After the observation period, mice 
were euthanized and necropsies performed on mice to identify gross pathologies. 
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2.4 PHARMACOKINETICS 
2.4.1 Mice, Sampling, and Tissue Preparation 
For the PK study, 3 female mice per treatment group per time point (5, 15, 30, 60, 120, 
240, 360, 1440 min) were administered a single dose of 4.0 mg/kg UPCDC-10205 in 10% 
Solutol™ HS by either lateral tail vain IV injection or PO administration by oral gavage. Control 
mice were delivered vehicle and euthanized at 5 and 1440 min. At the appropriate time point, 
mice were euthanized through CO2 asphyxiation and the following tissues collected: blood, liver, 
kidney, spleen, lung, heart, fat, skeletal muscle, and brain. Blood was collected through cardiac 
puncture in EDTA anticoagulated 22 gauge 1½ inch needles and 3 cc syringes, transferred to 
eppendorfs and centrifuged at 12,000xg for 3 min to separate plasma and red blood cells (RBCs). 
Urine and feces were from the 1440 min mice were collected from 0-360 and 360-1440 min 
group by housing in metabolic cages. Tissues were weighed and all samples were flash frozen 
using liquid nitrogen and stored at -80 °C until analysis. Necropsies were performed on all mice 
after euthanasia to identify gross pathologies. 
2.4.2 Quantitative LC-MS/MS Assay 
To support the PK study, a sensitive LC-MS/MS assay was developed to quantitate 
UPCDC-10205. A stable isotope, deuterated, 
2
H7 -UPCDC-10205, was used as the internal 
standard. The HPLC method utilized an Agilent 1100 binary pump and 1200 series autosampler 
(Santa Clara, CA). Chromatographic separation was achieved using a Phenomenex (Torrance, 
CA) Synergi Hydro-RP 80A column (4 µm particle size, 2 mm x 100 mm) at ambient 
temperature. Mobile phase solvent A was 0.1% formic acid (v/v) in acetonitrile, and mobile 
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phase solvent B was 0.1% formic acid (v/v) in water. The initial mobile phase was composed of 
50% solvent A pumped at 0.3 mL/min for 12.0 min, changed to 95% solvent A and was held 
constant for 4.0 min. At 16.1 min the percentage of solvent A returned to initial conditions of 
50% and allowed to equilibrate for 2 min followed by an injection of the next sample. Total run 
time was 18 min. The retention times were 9.6 and 9.4 min for UPCDC-10205 and 
2
H7 -
UPCDC-10205, respectively (Figure 5). The minor difference in RT can be attributed to the 7 
deuteriums on the internal standard which can cause slight differences interactions with the 
stationary phase on the column. 
 
Figure 5. Chromatogram from the quantitative LC-MS assay developed for the PK study. Shown is an 
LLQ sample (1 ng/mL) of UPCDC-10205, the internal standard (500 count offset) and an overlaid TIC 
chromatogram of a blank plasma sample (offset 1000 counts). 
 
A Waters Quattro Micro mass spectrometer (Milford, Massachusetts) was used in 
positive-ion MRM mode (4.5 kV capillary voltage, 30 V cone voltage, 450 °C desolvation 
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temp.) to monitor m/z 437.0>304 for UPCDC-10205 and m/z 444.0>304.0 for the internal 
standard. The postulated fragmentation pattern to obtain these transitions is seen in Figure 6. 
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Figure 6. Postulated UPCDC-10205 fragmentation pattern. Positive ionization monitored the parent m/z of 
437.0 and the product ion of 304.0 m/z. 
 
The calibration curve had a range of 1 to 1000 ng/mL (1, 3, 10, 30, 100, 300, 500, 1000 
ng/mL) and were prepared fresh in control mouse plasma obtained from Lampire Biological 
Labs Inc. (Ottsville, PA). Calibrators were prepared from serial dilutions of UPCDC-10205 in 
DMSO from a 1.0 mg/mL UPCDC-10205 stock solution that was stored at -80° C. Quality 
controls (QCs) were prepared in bulk using mouse plasma at three concentrations (2.5, 30, 800 
ng/mL) and aliquoted to 100 µL and stored at -80 °C until days of sample analysis. Two QCs at 
each level were analyzed alongside each study sample batch. 
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Assay performance and stability was evaluated as well. The effect of 3 freeze/thaw cycles 
on analyte concentrations in plasma was evaluated by assaying mid QCs after they had been 
frozen (-80 °C) and thawed on 3 separate days and comparing the results with those of that were 
not frozen. The stabilities of UPCDC-10205 in plasma during sample preparation were evaluated 
by assaying mid QCs before and after 4 h of incubation at room temperature. 
The validity of the assay in tissue homogenate was also tested by spiking untreated 
kidney and liver homogenate at the mid QC level and comparing it against a calibration curve 
prepared in mouse plasma. 
2.4.3 Assay Sample Preparation 
The sample volume was 100 µL of plasma or tissue homogenate. All samples were 
spiked with 10 µL of 0.2 μg/mL of the 2H7-UPCDC-10205 internal standard. Extraction and 
protein precipitation were accomplished using 500 µL of acetonitrile added to each sample. 
Samples were vortexed using a using a Vortex Genie 2 (Scientific Industries, Bohemia, NY) and 
centrifuged using an Eppendorf 5415C microcentrifuge (Westbury, NY). Supernatants were 
transferred to borosilicate glass tubes and placed in an evaporation apparatus (Multivap Nitrogen 
Evaporator, Organomation Associates, Berlin, MA) set at 37 °C and evaporated under a gentle 
stream of nitrogen (Valley National Gases, Inc., Pittsburgh, PA). Tissues were homogenized 
with 3 parts PBS (v/g) and values were corrected for dilution after analysis. 
2.4.4 Pharmacokinetic Analysis 
Samples from each mouse were analyzed using the quantitative LC-MS/MS assay. The 
values quantitated for each of the three mice per time point were averaged to obtain a mean that 
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served as the representative value for that time point. PK parameters (AUC0-t, AUC0-∞, T1/2, Vd, 
and Vss) were derived through non-compartmental analysis using PK Solutions (Summit PK, 
Montrose, CO) 
2.4.5 Protein Binding 
To assess the level of plasma protein binding of UPCDC-10205, a rapid equilibrium 
dialysis (RED) method (Thermo Scientific, Pittsburgh, PA) was used. Control mouse plasma was 
spiked at 1,000 ng/mL using a stock prepared in DMSO (organic < 0.1%). Four replicates of 200 
µL from the spiked 1000 ng/mL plasma were placed into the RED insert placed within a Teflon 
plate and 350 µL of PBS (pH 7.2) was aliquoted in the opposite side of the insert. The plate was 
placed on a shaker in an incubator at 37 °C for 4 hours. After this time, both saline and plasma 
portions were isolated and stored at -80 °C until analysis. Quantitation was achieved by creating 
standard curve in a matrix of 1:1 PBS:plasma and prepared and analyzed using the quantitation 
LC-MS/MS assay (2.4.2 and 2.4.3). Samples were diluted with either PBS or plasma to match 
the calibrator matrix. 
2.5 METABOLISM 
2.5.1 Metabolite Profiling 
To identify metabolites of UPCDC-10205, a series of LC-MS/MS methods were 
developed and utilized. Both plasma (IV 30 min 4 mg/kg) and urine (IV 0-6 hr 4 mg/kg) from 
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mice used in the PK study were separately evaluated and compared to their respective vehicle 
controls to identify unique traces in treated mouse samples. Unique traces were confirmed using 
a selected reaction monitoring (SRM) method that monitors specified ions. Unique trace 
potential metabolites were postulated by comparing the unique m/z trace to the parent UPCDC-
10205 m/z (437). 
2.5.2 Qualitative Metabolite Profiling LC-MS/MS assays 
Sample preparation was identical to the quantification method (see 2.2.3). The LC 
method was extended compared to the quantitative method to a run time of 75 minutes and used 
a gradient to spread out eluates using a Phenomenex Luna phenyl-hexyl column (3µ, 100X2.0 
mm). Mobile phase conditions for mobile phase A (acetonitrile with 0.1% formic acid) increased 
from the initial 5% to 55% at 0.3 mL/min for 60 min. This composition was then held at 55% for 
5 minutes then increased to 80% and held for 5 additional minutes until returning to initial 
conditions for equilibration during the final 5 minutes. 
To first identify metabolites, five sequential full mass (MS) scans were conducted using 
methods split into 100 m/z ranges to obtain a total scan range of 400-900 m/z. MS parameters 
were identical to the quantification method, with the exception of collision voltage and collision 
gas being turned off. 
Chromatographic peaks detected in urine or plasma were analyzed for their m/z trace 
composition. These m/z values were then used in an SRM MS method and the samples 
reanalyzed. To gain structural information, product ion scans (PIS) were used to identify 
potential areas of metabolic alterations. Five PIS were conducted simultaneously using unique 
collision voltages (10, 20, 30, 40, and 50) to get a variety of fragmentation products. Fragments 
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obtained through the PIS were compared to parent UPCDC-10205 fragmentation to elucidate 
metabolite structures using ChemDraw (PerkinElmer, Waltham, MS).  
The natural abundance of the stable isotope of 37-chlorine (
37
Cl) is approximately 25%, 
and this was employed to fingerprint UPCDC-10205 metabolites. Unique chromatographic peaks 
with m/z traces and m/z +2 were considered derived from UPCDC-10205. Additionally, during 
the PIS, product ions were analyzed to deduce structure and by analyzing potential fragmentation 
patterns to achieve a postulated metabolite. The presence of an overlapping +2 m/z trace on a 
product ion can yield information on the position of metabolic alterations. 
2.5.3 In Vitro Metabolism 
Microsomes were prepared and isolated from heterozygous Foxn1
nu
/Foxn1
+
female mice 
as described previously (2.2.1). The microsomal pellet was stored at -80 °C until measurement of 
protein concentration using the Biorad assay using BSA as a standard. The incubation for 
glucuronide metabolism was adapted from a previously published method to allow for a 1,000 
µL incubation volume.
37
 The incubation mixture contained 0.1 M phosphate buffer (pH 7.4), 
0.25 mg/mL microsomal protein concentration, 25 µg/mL alamethicin, 50 mM Tris-HCl, 10 mM 
MgCl2, and a 1,000 ng/mL drug concentration. The reaction was catalyzed with the addition of 5 
µM UPDGA. At 0, 15, 30, 45, and 60 minutes, 100 µL aliquots were sampled from the reaction 
mixture and 500 µL of acetonitrile added to terminate the reaction. 10 µL of 1.0 µg/mL internal 
standard (
2
H7 -UPCDC-10205) was added to each sample. Samples were processed as described 
previously. Samples were analyzed twice along with a standard curve produced in phosphate 
buffer matrix (pH 7.4) with 0.25 mg/mL BSA. The first analysis used the qualitative SRM LC-
MS assay to monitor a 613 m/z (437+176) glucuronide channel and the second used the 
 36 
quantitative MRM LC-MS assay to quantitate UPCDC-10205 substrate depletion. An incubation 
mixture without UPDGA cofactor was used as a negative control. 
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3.0  RESULTS 
3.1 SELECTION OF IN VIVO LEAD CANDIDATE 
3.1.1 LC-MS Assay 
The regression was weighted 1/y
2
 and fit quadratically. Figures of a triplicate standard 
curve and the respective R
2
 coefficient can be seen in Figure 7. A triplicate standard curve 
prepared prior to sample analysis revealed all four analytes were quantitated accurately (94.0-
109.5%) and precisely (CV<10.1%) (Table 1). The ratio of analyte area to internal standard area 
was used to back calculate the concentration based off of standard curves. Quantitation using 
linear regression proved unsuccessful in both SRM and MRM modes. Causes of non-linearity 
cannot be attributable to internal standard as levels remained constant during analysis. 
Differences of analyte ionization at varying concentrations are most likely the cause non-linear 
analyte to internal standard regression. Fitting the regression quadratically fit the data best and 
allowed for acceptable fit. 
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Figure 7. Triplicate standard results, quadratic regression curves (Y=A+B*X+C*X
2
) and R2 coefficients. 
(A) 864669 had an R
2
 of 0.994, (B) UPCDC-10205 had an R
2
 of 0.988, (C) UPCDC-10305 had an R
2
 of 0.995 (Δ), 
and (D) UPCDC-10540 had an R
2
 of 0.993.  
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Table 1. Assay performance data of the calibration samples for STAT3 inhibitors in phosphate buffer with 
0.5 mg/mL BSA 
Analyte 
Conc. Bias Precision 
(ng/mL) (%) (%) 
UPCDC-10205 30 1.0 9.4 
 100 -9.5 3.7 
 300 2.9 0.9 
 500 6.0 2.5 
 1000 -6.4 1.6 
UPCDC-10305 30 -1.0 7.8 
 100 0.0 1.1 
 300 1.3 1.1 
 500 -2.7 2.8 
 1000 0.6 5.1 
864669 30 -1.4 4.8 
 100 4.0 0.1 
 300 1.0 2.4 
 500 -3.3 7.3 
 1000 -3.9 2.0 
UPCDC-10540 30 -1.3 4.0 
 100 3.2 10.1 
 300 -3.8 5.5 
 500 -3.5 7.8 
 1000 0.4 9.5 
N=3; from a single triplicate results 
3.1.2 Substrate Depletion 
All sample concentrations fell within the standard calibration curve range. Concentration 
values were expressed as a % of the average starting concentration (0 min), seen in Figure 8. 
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Figure 8. Microsomal incubation of 864669 (◊), UPCDC-10205 (□), UPCDC-10305 (Δ), and UPCDC-
10540 (○) in A) linear and B) logarithmic y-axes. 
 
UPCDC-10205 had the largest proportion of the starting amount remaining after the 90 
minute incubation with 78.6% remained after 90 minutes compared to 14.1% for 864669, 12.3% 
A 
B 
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for UPCDC-10305 and 32.9% for UPCDC-10540. UPCDC-10205 was prioritized for in vivo 
experimentation based on this metabolic stability. 
3.2 TOXICITY STUDIES 
3.2.1 Single Dose Toxicity Study 
After administration of the maximum soluble dose of UPCDC-10205 at 4 mg/kg in 10% 
Solutol™ HS (0.4 mg/mL at a volume of 0.01 ml/g body weight), mice appeared normal and 
similar to vehicle dosed control mice. Clinical observations of the male and female mice 
indicated mice were healthy for the following 14 day observation period. All mice gained weight 
during the observation period with no apparent weight loss measured within the first 24 h after 
injection (Figure 9). Upon necropsy, no gross pathology was detected in any of the mice. One 
male had bite marks and local irritation on the skin between the scapulae where he had been 
bitten. The testes in this mouse were also smaller by about 30% compared to his cage mates and 
his spleen weight was slightly elevated, most likely due to infection. All other male mice 
appeared normal. The administrable maximum soluble dose at 4 mg/kg was determined to be the 
maximum tolerable dose (MTD). 
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Figure 9. Single dose toxicity study results of average mouse body weights (N=3) before and following a 
single IV injection of UPCDC-10205 at 4 mg/kg. Error bars represent ±1 SD. 
3.2.2 Multiple Dose Toxicity Study 
Because there were no obvious differences between sexes in both clinical observations 
and body weights between vehicle treated and UPCDC-10205 treated mice, only female Foxn 
nu/+ mice (N=20) were used for the multiple dose toxicity study. Groups of mice were dosed IV 
daily for five days (QDx5) with vehicle, 4 mg/kg, 2.7 mg/kg (2/3 single dose MTD), and 1.3 
mg/kg (1/3 single dose MTD). No signs or symptoms of toxicity were detected during the five 
day treatment period or the 14 day observation period. All mice gained weight during the study 
and weights between treatment groups showed no statistical differences to the vehicle control 
group (Figure 10). The mice remained healthy and there we no signs of gross pathology upon 
necropsy. 
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Figure 10. Multiple dose toxicity study. Averaged mouse body weights during and after QDx5 IV 
administration of UPCDC-10205 at IV daily for QDx5 with vehicle, 4 mg/kg, 2.7 mg/kg, and 1.3 mg/kg given to 
female mice. Error bars represent ±1 SD. 
 44 
3.3 PHARMACOKINETICS  
3.3.1 Quantitative LC-MS/MS Assay 
The regression was weighted 1/y
2
 and fit linearly (Y=A+B*X, Y=0.124+0.074*X) with 
and R
2
 coefficient of 0.998 (Figure 11). A triplicate standard curve prepared prior to sample 
analysis revealed UPCDC-10205 was quantitated accurately (93.7-108.1%) and precisely (CV< 
8.3%), see Table 2. The ratio of analyte area to internal standard area was used to back calculate 
the concentration based off of a standard curve. 
 
Figure 11. Triplicate standard curve results from the quantitative LC-MS/MS assay for UPCDC-10205 
showing calibrators (□), QCs (✕) and linear 1/y2 weighted regression curve (Y=0.124+0.074*X).  
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Table 2. Assay performance data of the calibration samples of UPCDC-10205 in mouse plasma. 
Conc. Bias Precision 
(ng/mL) (%) (%) 
1 -5.4 8.0 
3 6.3 8.3 
10 -3.0 0.8 
30 5.0 3.7 
100 -8.1 3.7 
300 -2.9 4.2 
500 0.4 3.4 
1000 1.8 3.7 
N=3; from a triplicate calibration curve prepared in mouse plasma. 
 
The recovery of UPCDC-10205 at the QCM was 46.2%, with a CV of 8.0%. Ion-suppression at 
the QCM was 8.2 with a CV of 6.6% (Table 3). The stability in plasma after 3 freeze thaw cycles 
(-80 °C to RT) at the QCM level was 111.5%. The stability in plasma after 4 hours at RT at the 
QCM level was 100.8% (Table 4). Recovery of the analytes in kidney and liver tissue 
homogenates analyzed against a plasma calibration curve ranged from 98.8– 105.1% with CVs 
ranging from 2.3 –7.4% ( 
Table 5).  
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Table 3. Recovery of UPCDC-10205 from mouse plasma and respective ion suppressions in mouse plasma 
extract, with coefficients of variation (CV). 
Concentration Recovery CV Ion suppression CV 
(ng/mL) (%) (%) (%) (%) 
QCM 30 46.2 8.0 8.19 6.6 
N=4  
 
Table 4. Stability of UPCDC-10205 under varying conditions. 
Storage condition Concentration Stability CV 
(ng/mL) (%) (%) 
F-T Cycle (3x) QCM 30 101.3 11.6 
Bench (RT) 4 h QCM 30 100.8 9.6 
N=4  
 
Table 5. Recovery of UPCDC-10205 from mouse liver and kidney homogenates. 
Tissue Concentration Recovery 
(%) 
CV 
(%) (ng/mL) 
Liver QCL 2.5 99.9 5.5 
 QCM 30 102.7 4.0 
 QCH 800 105.1 4.0 
Kidney QCL 2.5 102.1 7.4 
 QCM 30 98.8 4.9 
 QCH 800 100.4 2.3 
N=4 
3.3.2 Pharmacokinetics 
All PK parameters were analyzed using mean concentrations (N=3) of the three 
designated mice per time point. AUC0-t comparisons between administration forms are provided 
in Table 6 and Cmax and Tmax comparisons in Table 7. UPCDC-10205 levels in pooled urine from 
the IV 4 mg/kg mice represented 0.0011% (5.4 ng/mL) of the total amount administered for 0-6 
h collection and 0.0010% (1.6 ng/mL) for 6-24 h collection. Levels in pooled urine from the PO 
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4 mg/kg mice represented 0.0077% (42 ng/mL) of the total dose between 0-6 h. Quantitation of 
UPCDC-10205 in the 6-24 h as well as all urine samples from the PO 30 mg/kg in 1% CMC had 
concentrations below the LLQ. 
 
Table 6. UPCDC-10205 AUC0-t (ng·mL-1·h) in tissues as a measure of exposure 
  mg/kg Plasma F Liver Kidney Lung RBC Muscle Brain 
R
o
u
te
 IV 4 1021 100 1472 3240 2681 556 1634 1731 
PO 4 52.1 5.1 300 428 630 23.5 91.4 30.0 
CMC 30 25.7 0.3 542 272 186 - 140 33.4 
UPCDC-10205 AUC 0-t calculated non-compartmentally. F represents the fraction of IV plasma AUC0-t to 
PO plasma AUC0-t normalized to dose and multiplied by 100. 
 
Table 7. Cmax and Tmax of UPCDC-10205 in administered mice. 
 
mg/kg 
 
Plasma Liver Kidney Lung RBC Muscle Brain 
IV 4 
Cmax 1708 2779 4621 4494 980 1900 1643 
Observed 
Tmax 
0.08 0.08 0.08 0.08 0.08 0.25 0.25 
PO 4 
Cmax 35.0 220 308 414 16.0 51.2 15.4 
Observed 
Tmax 
0.5 0.08 0.5 0.08 0.5 1.0 1.0 
CMC 30 
Cmax 6.7 564 404 331 - 189 49.0 
Observed 
Tmax 
1.0 0.08 0.08 0.08 - 0.08 0.08 
Cmax and Tmax were derived from averages (N=3). 
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IV 4 mg/kg Pharmacokinetics 
The observed plasma Cmax for IV administered UPCDC-10205 was 1,707 ng/mL (± 455 
ng/mL) and occurred 5 minutes after injection. Plasma UPCDC-10205 levels were below the 
lower limit of quantitation (LLQ) by the 6 h time point. The in vivo profile appears biphasic 
indicating two compartments. PK parameters are listed in Table 8 and plasma, liver, lung, 
kidney, brain, skeletal muscle and red blood cell values can be viewed in Figure 12. The half-life 
in plasma was calculated non-compartmentally to be 0.6 hours and the AUC0-t to be 1021 
ng•h/ml. 
 
Table 8.  PK of IV UPCDC-10205 4 mg/kg dosed mice. 
 
Cmax 
Observed 
Tmax 
T1/2 AUC 0-t AUC 0-∞ Cl Vd Vss 
ng/mL h h ng/mL*hr ng/mL*hr mL/hr/kg mL/kg mL/kg 
Plasma 1708 0.08 0.6 1022 1022 3913 3378 2038 
 
      
% AUC 
Tissue/Plasma 
C
o
m
p
ar
tm
en
t 
Liver 2779 0.08 1.3 1472 1484 2695 145 
Kidney 4621 0.08 0.7 3240 3245 1232 318 
Lung 4494 0.08 0.6 2682 2683 1491 262 
RBC 980 0.08 0.7 556.3 560 7141 55 
Muscle 1900 0.25 0.5 1634 1635 2447 160 
Brain 1643 0.25 1.1 1731 1746 2291 171 
Results were analyzed non-compartmentally using composite concentration values of mice plasma or 
tissues (N=3). T1/2, AUC0-t, AUC 0-∞, Cl, Vd and Vss were obtained through non-compartmental analysis. 
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Figure 12. Concentration vs time results following IV administration at 4 mg/kg UPCDC-10205. Points 
represent the mean of the mice (N=3) and error bars represent ±1 SD. A) linear and B) logarithmic y axis. 
  
A 
B 
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PO 4 mg/kg Pharmacokinetics 
The Cmax for orally administered UPCDC-10205 at 4 mg/kg was 35.0 ng/mL and 
occurred at 0.5 hours after administration. Plasma UPCDC-10205 concentrations were below the 
LLQ after the 2 h time point. The in vivo profile appears triphasic indicating two compartments 
with an absorption phase. PK parameters are listed in Table 9 and the plasma, liver, lung, kidney, 
brain, skeletal muscle and red blood cell values can be viewed in Figure 13. The half-life was 
calculated non-compartmentally to be 0.60 h and the AUC0-t to be 52.1 ng•h/ml. To calculate the 
percent bioavailability, the following equation was used: 
𝐹 =
𝐴𝑈𝐶𝑂𝑟𝑎𝑙
𝐴𝑈𝐶𝐼𝑉
×
𝐷𝑜𝑠𝑒𝐼𝑉
𝐷𝑜𝑠𝑒𝑂𝑟𝑎𝑙
× 100 
Equation 1. Equation for percent bioavailability. 
 
The resulting oral percent bioavailability for UPCDC-10205 was determined to be 5.2%. 
 
Table 9. PK of PO UPCDC-10205 4 mg/kg dosed mice. 
 
Cmax 
Observed 
Tmax 
T1/2 AUC 0-t AUC 0-∞ Cl Vd Vss 
ng/mL h h ng/mL*hr ng/mL*hr mL/hr/kg mL/kg mL/kg 
Plasma 35.0 0.5 0.8 52 53.4 74858 88511 79810 
 
      
% AUC 
Tissue/Plasma 
C
o
m
p
ar
tm
en
t 
Liver 220 0.08 0.9 300 301 13287 563 
Kidney 308 0.50 1.2 428 435 9191 815 
Lung 414 0.08 0.4 629 630 6345 1180 
RBC 16 0.50 0.3 24 24 168859 44 
Muscle 51 1.00 0.5 91 92 43503 172 
Brain 15 1.00 0.4 29 31 131140 57 
Results were analyzed non-compartmentally using composite concentration values of mice plasma or 
tissues (N=3). T1/2, AUC0-t, AUC 0-∞, Cl, Vd and Vss were obtained through non-compartmental analysis.  
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Figure 13. Concentration vs time results following PO administration at 4 mg/kg UPCDC-10205 in 10% 
Solutol™ HS15. Points represent the mean of the mice (N=3) and error bars represent ±1 SD. A) linear and B) 
logarithmic y axis. 
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Carboxymethyl Cellulose PO 30 mg/kg Pharmacokinetics 
The Cmax for PO administered UPCDC-10205 at 30 mg/kg CMC suspension was 6.7 
ng/mL and occurred at 1.0 h after administration. The half-life was 3.4 h and calculated non-
compartmentally to be 3.4 h and the AUC0-t to be 25.7 ng·ml-1·hr. Dissolution from the 
suspension appeared to be the rate limiting step for absorption. PK parameters are listed in Table 
10 and plasma, liver, lung, kidney, brain, and skeletal muscle values can be viewed in Figure 14. 
Using Equation 1, the percent bioavailability was 0.3%. 
 
Table 10. PK of PO UPCDC-10205 30 mg/kg in 1% CMC dosed mice. 
 
Cmax 
Observed 
Tmax 
T1/2 AUC 0-t AUC 0-∞ Cl Vd Vss 
ng/mL h h ng/mL*hr ng/mL*hr mL/hr/kg mL/kg mL/kg 
Plasma 6.7 1.00 3.4 26 38 104699 507504 552212 
 
      
% AUC 
Tissue/Plasma 
C
o
m
p
ar
tm
en
t Liver 564 0.08 1.2 542 557 10462 1458 
Kidney 404 0.08 4.2 272 385 10403 1006 
Lung 331 0.08 3.6 185 238 16819 623 
Muscle 189 0.08 1.7 140 149 26897 389 
Brain 49 0.08 0.9 33 35 113948 92 
Results were analyzed non-compartmentally using composite concentration values of mice plasma or tissues (N=3). 
T1/2, AUC0-t, AUC 0-∞, Cl, Vd and Vss were obtained through non-compartmental analysis. 
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Figure 14. Concentration vs time results following PO administration at 30 mg/kg UPCDC-10205 in 1% 
CMC. Points represent the mean of the mice (N=3) and error bars represent ±1 SD. A) linear and B) logarithmic y 
axis. 
A 
B 
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3.3.2.1 Protein Binding 
The average from the 4 replicates in the plasma portion of the RED device was 1,282 
ng/mL and the value detected in the saline buffer portion was below the 1 ng/mL LLQ of the LC-
MS/MS assay. Although below the LLQ, using the back calculated concentration of the PBS 
concentration yielded an average value of 0.2 ng/mL (Table 11). The ratio of saline to plasma 
components multiplied by 100 yielded plasma protein binding amount of 99.98%. Defining the 
PBS samples as the LLQ (1 ng/mL) shows that plasma protein binding is >99.92% 
 
Table 11. RED analysis of UPCDC-10205 plasma protein binding 
Plasma PBS 
1 1260.0 1 0.24 
2 1242.2 2 0.23 
3 1288.9 3 0.23 
4 1336.2 4 0.24 
Mean 1281.8 Mean 0.23 
(1-([PBS]/[Plasma]))*100= 99.98 
LC-MS/MS analysis of RED protein binding experiment of UPCDC-10205 (n=4) after a four hour 
incubation at 37°C. 
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3.4 METABOLISM 
3.4.1 Results 
3.4.1.1 In vivo Metabolite Profiling 
Unbiased MS scans of urine (0-6 hour pooled) and plasma (30 min 4 mg/kg IV) produced 
multiple peaks within a range of 400 to 900 m/z, as seen in Figure 15A and Figure 16A, 
respectively. A single unique peak at a retention time of 43.6 min was found in treated mouse 
urine and plasma compared to vehicle control samples in both the 400-500 and 600-700 MS 
scans (Figure 15B and Figure 16B). MS scans from the 600-700 m/z range showed the 
underlying spectra composition of the 43.6 min peak in urine and plasma identified the m/z traces 
of 613 and 615 (Figure 17). 612 is the postulated molecular weight of a direct glucuronide 
conjugate of UPCDC-10205 (436 + 176 = 612). The presence of a smaller (1/3rd) +2 m/z trace of 
615 at the same RT confirm the presence of chlorine to fingerprint the glucuronide conjugate due 
to the natural isotopic abundance of 
37
Cl.  
Traces of 437 and 439 were also seen in urine and plasma at the same RT from the 400-
500 MS scan (Figure 18). 437 and 439 m/z traces at the 43.6 min peak are most likely due to in-
source fragmentation, where the glucuronide is cleaved from UPCDC-10205 conjugated 
glucuronide after chromatographic separation. Assay setup showed UPCDC-10205 to have an 
RT of 52.0 min and this was observed at this RT in the 400-500 MS scan in plasma but not urine 
(Figure 19). 
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Figure 15. Urine metabolite scan using five combined MS scans (400-900 m/z) for IV treated 4 mg/kg 
UPCDC-10205 and vehicle control mouse urine (pooled 0-6 hr) showing A) combined scans and B) the 40-50 min 
region of the 600-700 MS scan and a unique peak within treated mouse urine indicating a metabolite. 
A 
B 
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Figure 16. Plasma metabolite scan using five combined MS scans (400-900 m/z) for IV treated 4 mg/kg 
UPCDC-10205  and vehicle control mouse plasma (30 min) to show A) combined scans and B) the 40-50 min 
region of the 600-700 MS scan and a unique peak within treated mouse plasma indicating a metabolite. 
  
A 
B 
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Figure 17. Spectra of the unique the 43.6 min peak from the 600-700 MS Scan of IV treated 4 mg/kg in A) 
urine (pooled 0-6h) and B) plasma (30 min) along with their respective controls. 
  
A 
B 
 59 
 
Figure 18. Spectra of the unique the 43.6 min peak from the 400-500 MS Scan of IV treated 4 mg/kg in A) 
urine (pooled 0-6h) and B) plasma (30 min) along with their respective controls. 
  
A 
B 
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Figure 19. Spectra of the unique the 52.0 min peak from the 400-500 MS Scan of IV treated 4 mg/kg in 
plasma (30 min) and control plasma. 
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The SRM method conducted on plasma to confirm the presence of the glucuronide 
conjugate monitored 613 437 m/z yielded the similar results to the MS scan (Figure 20).  
 
 
Figure 20. Combined SRM chromatograms of the 613 and 437 m/z channels in treated IV 4 mg/kg 
UPCDC-10205 and vehicle control plasma. 
 
The product ion scan (PIS) of the 613 m/z channel (using a collision voltage of 20V) in 
plasma samples revealed unique product ions of 477 and 479 m/z at the 43.2 min RT peak 
(Figure 21). This spectra pattern reveals a similar 
37
Cl fingerprint seen in UPCDC-10205 spectra. 
The m/z is greater than the parent (437), indicating the glucuronide is most likely conjugated but 
a portion of the parent has been fragmented. Not enough information was available to use the 
477 m/z product ion to deduce any structural changes. Based on available electron pairs on the 
parent structure, it is postulated that the glucuronide is directly conjugated to either nitrogen of 
the pyrazole group of UPCDC-10205 (Figure 22). 
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Figure 21. A)Spectra of the 613 m/z product ion scan from the 43.6 min peak in both treated and vehicle 
control mouse plasma. Arrows show product ions of 437 (UPCDC-10205), 477 (unique) and 613 (unfragmented 
parent mass). B) Magnified spectra showing product ions of 477(
35
Cl) and 479 (
37
Cl). 
  
A 
B 
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Figure 22. Proposed metabolism of UPCDC-10205 to the conjugated N-glucuronide 
3.4.1.2 In vitro Metabolism 
Microsome incubation samples were analyzed twice. First using the qualitative SRM LC-
MS assay (2.5.2) and again to measure UPCDC-10205 using the quantitative assay (2.4.2).  
The SRM method monitoring the 613 m/z channel revealed increasing analyte/IS ratios at 
the 43.6 RT. A representative chromatogram from the 60 min incubation sample is shown in 
Figure 23. No 43.6 min peaks were detected in any 0 min or negative control samples. The 
generation of metabolite over the 60 min incubation can be seen in Figure 24. The 43.6 min peak 
also contained 437 m/z trace, indicating in-source fragmentation. The rate of metabolite 
formation is 0.068 response ratio/min/0.25 mg protein 
Measured concentrations of UPCDC-10205 divided by the time 0 concentration from the 
same incubation mixture were used to give a percentage of the starting amount. On average, only 
67% was remaining after the incubation (Figure 24). 
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Figure 23. SRM analysis from the permeabilized microsome incubation samples, with and without 
UPDGA cofactor. A) 613 m/z channel B) 437 m/z channel. 
 
A 
B 
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Figure 24. Microsome incubation with UPCDC-10205 with alamethicin and UPDGA to produce direct N-
glucuronide (613 m/z). Left axis shows quantification of UPCDC-10205 (□) represented by a percent of the starting 
amount. Right axis shows production of metabolites (○) represented as the ratio of analyte to internal standard 
values. 
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4.0  DISCUSSION 
The current standard of care for HNSCC has had little improvement on 5 year survival 
rates for patient’s suffering from the disease, especially for those with late stage, metastatic or 
recurrent HNSCC. The oncogene STAT3 has been found to be constitutively active in most 
cancer types including HNSCC.
1, 6-8
 While EGFR signaling is responsible for a portion of 
STAT3 activation, IL-6 signaling has been found to play a large role in the constitutive 
activation of STAT3, especially within the scope of HNSCC. To improve this outlook, newer 
therapies are being developed such as those that target IL-6 induced pSTAT3 like an mAb for 
IL-6 and STAT3 decoy oligonucleotides.
16, 38
 To date, no small molecule inhibitors of IL-6 
induced STAT3 activation have been developed. The long-term goal of our pursuit was to 
support the development of a small molecule to inhibit IL-6 induced of STAT3 activation that 
also preserves STAT1 tumor suppressive functionality. Four analogues from the 669 series of 
triazolothiadiazines were selected from a high-throughput screen based on meeting these criteria. 
Mouse liver microsomes were used because this study was a proof of principle to establish 
preclinical efficacy of STAT3 inhibition, and we therefore set the goal to optimize metabolic 
stability for this preclinical species. Human microsomes would be used as a confirmation later in 
the drug development process. The initial liver microsome incubation of the four analogues 
revealed that compound UPCDC-10205 was the most metabolically stable in the presence of 
phase 1 metabolizing enzymes, with approximately 80% of the compound remaining after a 90 
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min incubation. Based on this evidence, UPCDC-10205 was prioritized to be investigated in vivo 
to determine toxicity and PK. UPCDC-10205 demonstrated efficacy in inhibiting pSTAT3 from 
IL-6 induction in vitro using HNSCC cell lines with an IC50 of 2.1 µM and an IC100 of 4.0 µM. 
Both single and multiple dose UPCDC-10205 administrations to mice demonstrated no 
signs of toxicity. No changes in body weight, signs of decline in clinical health, or indications of 
gross pathology upon necropsy were observed in either toxicity study. The lack of toxicity may 
very well be due to the maximum soluble concentrations of UPCDC-10205, which limited the 
explored dose to 4 mg/kg or less (0.4 mg/mL in 10% Solutol™ HS). Other formulations were 
unable to achieve higher concentrations.  
Pharmacokinetics 
Poor PK properties of new chemical entities are a major reason they fail during drug 
development.
39
 Describing PK parameters can help investigators evaluate whether the new 
compound can potentially reach its intended target of action for long enough duration and at an 
appropriate concentration to achieve its intended effect as well as describing the in vivo fate of 
the drug. In these studies, we successfully determined the absorption, distribution, metabolism 
and elimination while simultaneously examining the potential of using UPCDC-10205 as an oral 
agent. 
Absorption 
Comparison of IV and PO dosage forms revealed UPCDC-10205 to be poorly 
bioavailable (5.2%) from a solution. Major factors limiting drug absorption are permeability 
across the epithelial lining of the GI tract, tissue binding, the first pass effect, dissolution and 
degradation in the gut. Furthermore, transporters can play a role in decreased absorption and 
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bioavailability. PgP is also known to decrease the bioavailability of a variety of different anti-
cancer drugs.
40
 
The first pass effect may limit bioavailability of UPCDC-10205. Absorptive transport 
through the hepatic portal vein allows liver exposure of UPCDC-10205 to hepatocytes 
containing UPDG enzymes. Biotransformation to the glucuronide prior to systemic exposure 
would contribute to the observed low bioavailability. 
The permeability of UPCDC-10205 does not seem to impede absorption as seen in its 
rapid and extensive distribution observed as exposure in tissues compared to plasma. PK analysis 
shows slower tissue elimination than plasma elimination, which may be attributable to 
compound binding to lipids or protein in tissues. Corroborating this indication, tissue exposure in 
relation to plasma exposure shows PO dosing resulted in elevated UPCDC-10205 exposure in 
liver and lungs compared to IV administered mice. Orally administered drugs must pass these 
two organs prior to systemic distribution and can limit the bioavailability by exposing them to 
metabolism and biliary excretion.  
High tissue binding in peripheral compartments that must be traversed prior to systemic 
exposure can partially explain the low bioavailability. Systemic availability of the drug could be 
limited in this capacity as only drug not bound to tissue is available for further distribution. 
Quantification of drug concentrations in tissues does not discriminate between bound and 
unbound. Thus, levels reported may indicate high exposure but in reality the unbound fraction 
available for distribution may be extremely limited by binding. 
It is likely that dissolution negatively affected the bioavailability (0.34%) of the 30 mg/kg 
UPCDC-10205 suspension in 1% CMC. This is an example of flip-flop pharmacokinetics where 
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the rate of absorption is slower than the rate of elimination and the rate of absorption becomes 
rate-limiting to elimination, resulting in an artificially increased half-life.
41
 
Distribution 
The Vd observed was high, as determined by plasma analysis, and is corroborated by 
exposure of UPCDC-10205 observed in tissues. Highly perfused tissues, such as kidney, had 3 
times the exposure compared to plasma. The Tmax for kidneys was the same as plasma (5 
minutes), indicating rapid distribution. Skeletal muscle, which is poorly perfused, had an 
approximately 50% increased exposure compared with plasma and had an increased Tmax of 15 
minutes. Brain exposure was similar to skeletal muscle, and demonstrates the ability of UPCDC-
10205 to traverse the blood brain barrier. Analysis of RBCs did not indicate high levels of RBC 
drug uptake that could contribute to the observed volume of distribution. Plasma protein binding 
can increase Vd and limit the free fraction available for distribution.
42
 The 99.9% plasma protein 
binding of UPCDC-10205 must contribute to the Vd but did not majorly limit distribution, as 
most tissue exposure was higher than plasma and this highlights the permeability of UPCDC-
10205. Tissue binding may also contribute to Vd but was not investigated.  
Metabolism 
The first liver microsome stability study was used as a relative measure to prioritize one 
of the 669 series analogues by selecting against susceptibility to oxidative biotransformation. In 
vivo administration yielded a higher clearance and shorter half-life than anticipated. 
Identification of the direct-glucuronide metabolite as the only identified biotransformation 
validates the results of the original microsome incubation. It produced translatable results in that 
no major oxidative metabolites were identified in vivo. While translatable, the incubation did not 
allow for examination of phase II metabolic pathways as phase I are generally the rate limiting 
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step. The generation of the direct glucuronide metabolite in vivo may also contribute to the low 
bioavailability due to the first pass effect. 
Screening for metabolites in urine and plasma proved arduous due to the presence of the 
vehicle. Solutol™ HS15 is an emulsifying agent consisting of mono- and disesters of 12-
hydroxystearic acid and free polyethyleneglycol that are extensively hydrolyzed in vivo.
43
 The 
vehicle appeared at many mass ranges and may have masked potential metabolites during MS 
scans. Solutol™ HS15 is known to contain 613 m/z traces, 43 but the unique 613 m/z trace from 
the 43.6 min peak in treated mice indicates a true metabolite. This was confirmed in vitro where 
no Solutol™ HS15 was present. While the in vitro glucuronidation experiment revealed 67% 
substrate depletion, this number may be composed of other unknown biotransformations that 
took place without the addition of necessary cofactors. 
Elimination 
Elimination is a combination of both metabolism and excretion. Excretion is largely 
accomplished by the kidneys and liver (via biliary secretion). Renal excretion is a combination of 
glomerular filtration, active secretion, and reabsorption. The size of UPCDC-10205 should 
permit glomerular filtration based on its MW of 436 a.m.u. This is below the glomerular 
threshold so the compound should freely be filtered into the renal tubule. The lipophilic nature of 
UPCDC-10205 also make it a likely candidate for rapid reabsorption from the lumen back into 
the blood stream. Despite the fact that kidneys had high exposure to UPCDC-10205, urine 
analysis revealed negligible UPCDC-10205 in urine demonstrating that renal excretion is not a 
major contributor to clearance. Because renal excretion was minimal, metabolism was thought to 
play a major role in elimination. The low urine amounts of UPCDC-10205 could also be 
attributed to high plasma protein binding as only free drug is able to be renally filtered. 
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The glucuronide metabolite is also below the renal threshold (612 a.m.u) but was present 
in urine. The presence of metabolite and not the parent in urine is most likely attributable to the 
increased polarity that the glucuronide adds that would prevent reabsorption. The metabolite is 
most likely less protein bound as well, meaning more free metabolite is available for renal and 
biliary excretion. 
It is possible that biliary excretion of UPCDC-10205, in both its parent and metabolic 
forms, contributes to its elimination. Reported molecular weight cutoffs for biliary excretion vary 
between species, with the cutoff in rats being around 250 and humans being between 500 and 
600, although more recent reports suggest that there is no clear threshold.
44, 45
 The molecular 
weight of UPCDC-10205 falls above the threshold for rats, meaning it is susceptible to biliary 
excretion. It is slightly below threshold for humans, which could allow for less biliary excretion 
of UPCDC-10205 and increased half-life comparted to rodents. These cutoffs also apply to the 
metabolite, which is above the thresholds of both species, making it a likely candidate for biliary 
excretion as well. Biliary excretion may also contribute to low bioavailability, with drug 
absorbed being eliminated unchanged. Reabsorption after biliary excretion is unlikely to have a 
significant effect based on the observed bioavailability. 
Metabolic stability is important in selecting a successful drug candidate.
46, 47
 It is also 
important to analyze in vitro metabolic stability if oral use is a goal of candidate selection 
because presystemic metabolism can limit bioavailability.
48
 Choosing a candidate based on 
metabolic stability, instead solely on in vitro potency, often yields more efficacious leads.
49, 50
 In 
vitro metabolic stability is used a predictor for in vivo metabolic clearance.
46
 Prioritization of 
UPCDC-10205 was based on metabolic stability conveyed from the initial microsome incubation 
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but only accounted for phase I metabolism with the rationale that cyp P450s account for the 
metabolism for about 90% of all drugs.
46, 48
 
There are many reasons to prioritize the use of microsomes. Besides practical aspects of 
cost and complexity, these include the ideas that cytochrome P450 metabolism is usually rate 
limiting steps in biotransformation and cytochrome P450 metabolism is the major ADME reason 
for drug failure during development.
48
 The major disadvantage for using microsome screens as a 
measure of metabolic stability is that they do not represent the complete in vivo system of 
metabolizing enzymes and only have the capacity to stably represent CYPs and UGTs. The 
promotion of a compound from the 669 series was designed as a relative measure of metabolic 
stability due to cytochrome P450s being the major factor in metabolism of drugs.
46
 
Prioritization could have been accomplished using hepatocytes or liver slices to 
accommodate all forms of enzymatic biotransformation. While these methods are more 
representative of human metabolism they can have disadvantages such as having reduced 
enzymatic activity by lacking sufficient cofactor production in cells.
51, 52
 Direct glucuronidation, 
as identified with UPCDC-10205, does not require prior phase I metabolic biotransformation.
52
 
The 20% substrate depletion of UPCDC-10205 observed in the initial lead selection incubation 
did not account for glucuronidation. The incubation conducted to produce the glucuronide 
depleted approximately 25% of UPCDC-10205 in 60 minutes, which demonstrates its 
susceptibility to direct conjugation. 
Two other analogues from the 669 series contain the pyrazole groups postulated as the 
site for direct glucuronidation making it possible they may also experience the observed direct 
glucuronidation. UPCDC-10540 has a methyl group attached to the pyrazole which may prevent 
susceptibility to N-glucuronidation. UPCDC-10540, UPCDC-10305 and 864669 would likely 
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experience more extensive metabolism than UPCDC-10205 due to their higher levels of phase I 
metabolism observed in vitro. These phase I metabolites may also increase the metabolic 
contribution to clearance as well their potential for non-direct glucuronidation. 
Pyrazole groups are a common motif used in small molecule drugs. The available 
electron pair on either nitrogen of the pyrazole group is able to be targeted by UGTs for 
conjugation. N-glucuronidation is largely accomplished through UGT isoforms 1A4 and 2B10 
and the enzyme amounts of these isoforms is higher in humans than other animals.
53
 These 
enzymes exist primarily in the liver, but UGT1A4 expression has also been detected in kidneys, 
and may also contribute to metabolic clearance.
54
 Glucuronidation can also occur in intestinal 
microsomes, which could also to contribute to decreased bioavailability.
55
 Extrahepatic 
glucuronidation can contribute to the clearance observed in the PK studies, especially in orally 
delivered UPCDC-10205. Other compounds subjected to direct N-glucuronidation by UGT 2B10 
include tertiary or cyclic amines.
56
 Scaling of the in vivo or in vitro glucuronidation results to 
humans seems unpredictable as both UGT2B10 and 1A4 exhibit high levels of variability in 
expression from analysis on human liver samples.
57
 UGT2B10 appears to have a higher affinity 
for tertiary and cyclic amines than UGT 1A4 but expression amounts in the liver are not equal.
56
 
Extrapolation of metabolic rates to human appears difficult due to species variability of 
glucuronidation rates.
58
 Additionally, the scaling of in vitro glucuronidation rates to in vivo 
generally underestimates clearance due to glucuronidation.
59
 Direct N-glucuronidation to 
pyrazole groups of small molecule drugs has been observed previously.
60-63
 
Other compounds undergoing extensive N-glucuronidation on pyrazole groups have been 
optimized to add substituents to the pyrazole in order to decrease susceptibility to direct 
glucuronidation.
63
 Molecular addition of electronegative groups may reduce nucleophilic 
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tendencies of pyrazole nitrogens and decrease availability for direct glucuronidation. This 
method has been explored with other pyrazole containing small molecules that underwent rapid 
N-glucuronidation.
64
 Alterations to UPCDC-10205 could potentially increase bioavailability and 
decrease metabolic clearance.  
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5.0  CONCLUSIONS AND FUTURE DIRECTIONS 
The aim of this project was to prioritize an IL-6 induced STAT3 inhibitor that was 
selective for STAT3 and to describe the toxicology, PK and metabolism of the compound. 
UPCDC-10205 was prioritized for in vivo administration to determine if the compound deserves 
further preclinical investigation. While UPCDC-10205 demonstrated in vitro potency and 
selectivity, several factors were identified in vivo that limit UPCDC-10205’s potential as a future 
clinical therapeutic. Preclinical pharmacokinetics create a bottleneck for anticancer drug 
development, so prioritization and evidence gathering on PK is of importance. Solubility, 
metabolism, and plasma protein binding have been identified through these studies as the major 
limiting factors of UPCDC-10205’s potential. PK and bioavailability are the 3rd most common 
cause of drug development attrition.
39
 While the percentage of drugs whose attrition is related to 
DMPK has been lowered over the last 30 years, it still accounts for approximately 11% of drug 
failures.
65
 
Future investigations for the development of small molecule inhibitors of IL-6 induced 
pSTAT3 should investigate the structure activity relationship (SAR) of the 669 analogue series 
with the IL-6/STAT3 signaling cascade. An SAR may allow elucidation of active chemical 
epitopes and potentially help reduce future metabolic lability, decrease protein binding, and 
increase solubility while simultaneously maintaining potency and selectivity. 
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